SOURCE: Milestone Scientific, Inc.

Milestone Scientific, Inc.

May 26, 2016 07:30 ET

Milestone Scientific Announces Completion of Enrollment in Clinical Trials for Its Epidural Instrument

LIVINGSTON, NJ--(Marketwired - May 26, 2016) - Milestone Scientific Inc (NYSE MKT: MLSS) today announced it has completed enrollment in its COMPASS Study (CompuFlo® Assessment Study), a randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System. The clinical trial for the epidural instrument reached its target of enrolling 400 patients and consists of two separate arms: (i) pain management; and (ii) labor and delivery. Both arms will be compared against the current medical standards of care. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo technology in identifying and confirming the epidural space location.

Leonard Osser, Chief Executive Officer of Milestone Scientific, stated, "We are pleased to have achieved our enrollment target and expect to complete the trial in the coming weeks."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Safe Harbor Statement 
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2015. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • Contact:

    David Waldman or Natalya Rudman
    Crescendo Communications, LLC
    Tel: 212-671-1020